ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
REGENXBIO Inc

REGENXBIO Inc (RGNX)

13.50
0.79
(6.22%)
Closed July 23 4:00PM
13.50
0.00
( 0.00% )
Pre Market: 4:22AM

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
13.50
Bid
13.50
Ask
14.00
Volume
-
0.00 Day's Range 0.00
10.49 52 Week Range 28.80
Market Cap
Previous Close
13.50
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
531,979
Shares Outstanding
49,255,966
Dividend Yield
-
PE Ratio
-2.52
Earnings Per Share (EPS)
-5.35
Revenue
90.24M
Net Profit
-263.49M

About REGENXBIO Inc

Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno-associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neur... Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno-associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Headquarters
Wilmington, Delaware, USA
Founded
1970
REGENXBIO Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker RGNX. The last closing price for REGENXBIO was $13.50. Over the last year, REGENXBIO shares have traded in a share price range of $ 10.49 to $ 28.80.

REGENXBIO currently has 49,255,966 shares outstanding. The market capitalization of REGENXBIO is $664.96 million. REGENXBIO has a price to earnings ratio (PE ratio) of -2.52.

RGNX Latest News

REGENXBIO Announces Expansion of AFFINITY DUCHENNE® Trial to Include a New Cohort of Younger Patients

REGENXBIO Announces Expansion of AFFINITY DUCHENNE® Trial to Include a New Cohort of Younger Patients PR Newswire ROCKVILLE, Md., June 24, 2024 Company to begin enrollment of patients aged 1-3...

REGENXBIO Announces Successful Pre-BLA Meeting with FDA to Support Accelerated Approval Pathway for RGX-121 for the Treatment of MPS II

REGENXBIO Announces Successful Pre-BLA Meeting with FDA to Support Accelerated Approval Pathway for RGX-121 for the Treatment of MPS II PR Newswire ROCKVILLE, Md., June 18, 2024 Aligned with FDA...

REGENXBIO Announces Leadership Transition

REGENXBIO Announces Leadership Transition PR Newswire ROCKVILLE, Md., June 12, 2024 Curran Simpson, Chief Operating Officer, Appointed as President and CEOCo-Founder Kenneth T. Mills to Step Down...

REGENXBIO to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

REGENXBIO to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference PR Newswire ROCKVILLE, Md., June 5, 2024 ROCKVILLE, Md., June 5, 2024 /PRNewswire/ -- REGENXBIO Inc...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.080.59612518628913.4213.8112.1248440313.03392605CS
41.2810.474631751212.2213.8110.4952760912.1181978CS
12-1.93-12.508101101715.4317.5210.4953197913.35049361CS
26-0.91-6.3150589868114.4128.810.4963269516.90716619CS
52-4.71-25.864909390418.2128.810.4954257017.04958685CS
156-21.34-61.25143513234.8446.4610.4945216822.88391544CS
260-35.41-72.398282559848.9154.9710.4944209628.79364879CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
NUZENuZee Inc
$ 2.42
(134.95%)
6.17M
DRMADermata Therapeutics Inc
$ 2.59
(99.23%)
11.09M
HOTHHoth Therapeutics Inc
$ 1.50
(54.33%)
10.72M
PIRSPieris Pharmaceuticals Inc
$ 11.87
(48.75%)
86.51k
BBLGBone Biologics Corporation
$ 1.85
(48.00%)
3.49M
VWEVintage Wine Estates Inc
$ 0.073
(-34.76%)
935.54k
CONNConns Inc
$ 0.3502
(-30.93%)
135.81k
SAGESage Therapeutics Inc
$ 9.50
(-27.37%)
6.93k
TCBPTC BioPharm Holdings PLC
$ 0.60
(-25.00%)
502
ATPCAgape ATP Corporation
$ 0.162
(-24.65%)
496.56k
ALLRAllarity Therapeutics Inc
$ 0.2135
(28.23%)
29.51M
DRMADermata Therapeutics Inc
$ 2.59
(99.23%)
11.09M
HOTHHoth Therapeutics Inc
$ 1.50
(54.33%)
10.72M
SLNASelina Hospitality PLC
$ 0.0291
(11.92%)
9.93M
NUZENuZee Inc
$ 2.42
(134.95%)
6.17M

RGNX Discussion

View Posts
crudeoil24 crudeoil24 3 years ago
36M share trading float.

RGNX
👍️0
crudeoil24 crudeoil24 3 years ago
AbbVie And REGENXBIO Announce Eye Care Collaboration; AbbVie To Pay REGENXBIO $370M Upfront Payment And Up To $1.38B In milestones
6:31 am ET September 13, 2021 (Benzinga) Print
AbbVie (NYSE:ABBV) and REGENXBIO Inc. (NASDAQ:RGNX) today announced a partnership to develop and commercialize RGX-314, a potential one-time gene therapy for the treatment of wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR) and other chronic retinal diseases. RGX-314 is currently being evaluated in patients with wet AMD in a pivotal trial utilizing subretinal delivery, and in patients with wet AMD and DR in two separate Phase II clinical trials utilizing in-office suprachoroidal delivery.

Under the collaboration, REGENXBIO will be responsible for completion of the ongoing trials of RGX-314. AbbVie and REGENXBIO will collaborate and share costs on additional trials of RGX-314, including the planned second pivotal trial evaluating subretinal delivery for the treatment of wet AMD and future trials. AbbVie will lead the clinical development and commercialization of RGX-314 globally. REGENXBIO shall participate in U.S. commercialization efforts as provided under a mutually agreed upon commercialization plan.

"We are committed to finding solutions for patients living with difficult-to-treat retinal diseases and to helping preserve and protect our patients from visual impairment and devastating vision loss," said Tom Hudson, MD, senior vice president, R&D, chief scientific officer, AbbVie. "In collaboration with REGENXBIO, we aim to make a remarkable impact for the millions of patients suffering from vision loss associated with retinal diseases."

"AbbVie is a strong, complementary partner for REGENXBIO. We expect to leverage AbbVie's global developmental and commercial infrastructure within eye care with our expertise in AAV gene therapy clinical development and deep in-house knowledge of manufacturing and production to continue the development of RGX-314," said Kenneth T. Mills, president and chief executive officer of REGENXBIO.

Under the terms of the agreement, AbbVie will pay REGENXBIO a $370 million upfront payment with the potential for REGENXBIO to receive up to $1.38 billion in additional development, regulatory and commercial milestones. REGENXBIO and AbbVie will share equally in profits from net sales of RGX-314 in the U.S. AbbVie will pay REGENXBIO tiered royalties on net sales of RGX-314 outside the U.S. In addition, REGENXBIO will lead the manufacturing of RGX-314 for clinical development and U.S. commercial supply, and AbbVie will lead manufacturing of RGX-314 for commercial supply outside the U.S.
👍️0
StockLearner2011 StockLearner2011 5 years ago
https://www.google.com/amp/s/www.nasdaq.com/article/4-gene-therapy-players-likely-to-become-buyout-targets-in-2019-cm1125990/amp
👍️0
StockLearner2011 StockLearner2011 5 years ago
I believe the buyout is in a distance future. JUNO has the same trading behavior before buyout was announced!
👍️0
Zmill Zmill 5 years ago
is there an argument for a BO? https://msmoneymoves.com/2019/05/28/could-this-biotech-stock-get-bought-for-5-5-billion-either-way-im-buying-it/
👍️0
BlackEyePatch BlackEyePatch 5 years ago
Strong buy @ 50!!!!
👍️0
stocktrademan stocktrademan 6 years ago
RGNX buy 66.90























normal chart




log chart



👍️0
StockLearner2011 StockLearner2011 6 years ago
Hope no more form 4s for insider selling
👍️0
StockLearner2011 StockLearner2011 6 years ago
Let’s see how tomorrow will be
👍️0
StockLearner2011 StockLearner2011 6 years ago
Why insiders sold at $34 and $37 while the target price is $90? Anybody has any clue?
👍️0
StockLearner2011 StockLearner2011 6 years ago
$45 soon! Yummy
👍️0
stocktrademan stocktrademan 8 years ago
RGNX bullish 14.39



normal chart


log chart

👍️0
protagonist12 protagonist12 8 years ago
Agreed, would like to to see the stock come down to single digits before buying though. Still only in preclinical trials and burning a ton of cash.
👍️0
floWteiuQ floWteiuQ 8 years ago
Interesting play here for the long term. Very good technology with a lot of prospects for them and licensing.
👍️0
protagonist12 protagonist12 9 years ago
RGNX no bid support, too early still, listed VC...
👍️0

Your Recent History

Delayed Upgrade Clock